Diabetes Mellitus após Terapêutica com Peginterferão-Alfa 2ª para Hepatite Viral C Crónica

 

M. J. Osório, L. Iurescu, L. Bagulho, C. Marques, J. Esteves, J.Almeida, T. Matias

 

Resumo

Tem sido descrita na literatura a existência de uma relação entre Hepatite Viral C Crónica e Diabetes mellitus tipo II, devido à hepatopatia crónica ou uma sua manifestação extra-hepática. O aparecimento de Diabetes mellitus tipo 1 em doentes medicados com interferão-alfa tem sido recentemente relacionado com o aparecimento de anticorpos anti-pancreáticos ou com o aumento da sua titulação. Este artigo ilustra um caso de diabetes mellitus tipo 1 inaugural, grave, 5 meses após ter sido iniciada terapêutica combinada com peginterferão-alfa e ri-bavirina. O nosso objectivo é interrogar a importância da avaliação prévia do risco da ocorrência de diabetes mellitus durante o tratamento da hepatite viral.

 

Summary

It has been reported the existence of an association between Chronic Viral Hepatitis C and type 2 Diabetes mellitus, probably as a manifestation of the chronic hepatic disease and/or one of its extra-hepatic manifestations. Recently, it has been reported the appearance of type 1 Diabetes mellitus after treatment with interferon-alpha, associated with the appearance of anti-pancreatic antibodies or with an increase in their titration. We pretend to illustrate a severe case of new-onset type 1 diabetes mellitus, 5 months after combined treatment with interferon-alpha and ribavirin. Our objective is to enhance the importance of evaluate the risk of developing diabetes mellitus with the treatment.

 

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

BIBLIOGRAFIA

1. Relatório de Consenso e Recomendações para o Diagnóstico e Tratamento das Hepatites B e C. GE vol. 11.

2. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006 May; 7(5): 451-6.        [ Links ]

3. Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol. 2005 Mar; 51(1): 55-61. Março/Abril 2004 - suplemento.

4. Bohbot NL, Young J, Orgiazzi J, Buffet C, Francois M, Bernard-Chabert B, et al. Interferon-(alpha)-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves diasease. Eur J Endocrionol 2006 March; 154(3): 367-372.

5. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Mangbisi OG. Onset of type 1 diabetes mellitus during peginterfe-ron alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol.2006 Jun;18(6): 689-92.

6. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Review article: type 1 diabetes in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18: 549-558.

7. Ahmed F, Jacobson I, Hargrave T, Lawitz E, Terrault N, Migicovsky B, et al. Diabetes mellitus of new onset during pegylated> interferon and ribavirin therapy for chronic hepatitis C: Observations from the WIN-R Trial. Hepatology 2003 October. 38(4 Suppl.1); 730A-731A.

8. Fabris P, Betterle C, Greggio N, Zanchetta R, Bosi E, Biansin M, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. Journal of Hepatology 1998;28: 514-517.

9. Eibi N, Gschwantler M, Fererci P, Eibi MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol. 2001 Mar; 13(3): 295-8.

10. Yazicioglu G, Isitan F, Altunbas H, Suleymanlar I, Ozdogan M, Balci MK, et al. Insulin resistance in chronic hepatitis C. Int J Clin Pract 2004 November; 58,11: 1020-1022.

11. Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications. 2006 Mar-Apr; 20(2): 113-20.

12. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; Aug; 35 (2): 272-83.

13. Nemesansky E, Pusztay M, Csepregi A. Effects of interferon treatment on the glucose metabolism of patients with chronic hepatitis C. Eur J Med 2000 Jun; 11(3): 151-155.

14. Anton C, Trifan A, Stanciu GO, Malgarinos G. Seizures during the treatment with interferon for chronic C hepatitis. Cleve Clin Med. 2005 Nov;72(11): 1005-8,1010-4,1016.

15. Camassa, Casella G, Somma A, Perego D, Baldini V. Seizure during alfa-interferon therapy. Minerva Gastroenterol Dietol. 2004 Dec; 50(4): 351-2.

16. Seno H, Inagaki T, Itoga M, Miyaoka T, Ishino H. A case of seizures 1 week after the cessation of interferon-alfa therapy. Psychiatry Clin Neurosci. 1999 Jun; 53(3): 417-20.

 

 

Hospital de São José, Lisboa, Portugal.

 

Correspondência

Maria Joana Osório

Alameda D. Afonso Henriques, 44

1900-181 Lisboa

Tel.: 218487307

Tlm.: 965368852

 

Recebido para publicação: 03/08/2006

Aceite para publicação: 04/04/2007